MYO
Myomo, Inc.
MYO has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
MYO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
MYO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MYO PE Valuation
MYO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MYO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
MYO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MYO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.35 | -$0.07 |
| Q2 2026 | -$0.34 | -$0.12 |
| Q1 2026 | -$0.36 | -$0.22 |
| Q4 2025 | -$0.37 | -$0.21 |
| Q3 2025 | -$0.28 | -$0.05 |
| Q2 2025 | -$0.22 | +$0.04 |
| Q1 2025 | -$0.14 | +$0.13 |
| Q4 2024 | -$0.16 | +$0.12 |
MYO is still losing money, but far less than before: $0.35 per share over the past year, against $19.35 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MYO on earnings quality, reporting a profit while its opponent remains loss making.
MYO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.3M | +22% |
| Q2 2026 | $11.7M | +21% |
| Q1 2026 | $10.1M | +2.9% |
| Q4 2025 | $11.4M | -5.9% |
| Q3 2025 | $10.1M | +9.6% |
| Q2 2025 | $9.7M | +28% |
| Q1 2025 | $9.8M | +162% |
| Q4 2024 | $12.1M | +154% |
MYO has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | +21 points |
| Q2 2026 | -19% | +28 points |
| Q1 2026 | -31% | +4.6 points |
| Q4 2025 | -24% | -22 points |
| Q3 2025 | -35% | -25 points |
| Q2 2025 | -48% | -33 points |
| Q1 2025 | -36% | +68 points |
| Q4 2024 | -2% | +49 points |
MYO's operating margin was −14% last quarter, up 21 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MYO on profitability, with a higher operating margin.
MYO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$1.5M |
| Q2 2026 | -$2M | +$8.1M |
| Q1 2026 | -$2.5M | +$822.4K |
| Q4 2025 | $98.1K | -96% |
| Q3 2025 | -$2.9M | -$1.1M |
| Q2 2025 | -$10.1M | -$8.1M |
| Q1 2025 | -$3.3M | -$42.2K |
| Q4 2024 | $2.5M | +$4.9M |
MYO has burned cash in almost every quarter: −$6M over the past year, against −$14M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MYO on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +873K shares |
| 1 year | +3.3% | +1.4M shares |
| 3 years | +24% | +8.3M shares |
| 5 years | +673% | +37.9M shares |
| Available history | +7768% | +43M shares |
MYO has 44M diluted shares, up 3.3% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MYO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MYO Net Leverage
MYO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MYO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 20.7 | Neutral |
MYO's weekly RSI is 48 (neutral) and its Stochastic is 21 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MYO PE vs Healthcare Sector
MYO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MYO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.34 | 9.7% below |
| 20 week MA | $1.32 | 8.3% below |
| 50 week MA | $1.08 | 12% above |
| 100 week MA | $2.14 | 43% below |
| 200 week MA | $2.36 | 49% below |
MYO's trend is mixed: it's above one of its five weekly moving averages, and 49% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
MYO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.08 | $6.94 | -24% |
| 2021 | $6.94 | $7.90 | +14% |
| 2022 | $7.90 | $0.44 | -94% |
| 2023 | $0.44 | $5.01 | +1039% |
| 2024 | $5.01 | $6.37 | +27% |
| 2025 | $6.37 | $1.02 | -84% |
| 2026 YTD | $1.02 | $1.21 | +19% |
MYO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.